VBIO

Valion Bio, Inc.
CAPPED RATING

Valion Bio, Inc. (VBIO) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C+
Factor Score 2.5 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
D
Factor Score 1.2 / 5.0
Momentum
F
Factor Score 0.3 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio N/A
EV / EBITDA -1.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -88.4%
Price Return 12M -99.1%
Catalyst Signal 0.00
Market Cap $1.1M
TTM Revenue -$86.0K
Price / Sales -13.3
ROE -459.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) C+ (2.5) D (1.2) F (0.3) C+ (2.6) D+ (1.8)
2026-11-08 C+ (2.5) C+ (2.5) D (1.2) F (0.3) C+ (2.6) D+ (1.8)
2026-11-01 C+ (2.5) C+ (2.5) D (1.4) F (0.3) C+ (2.7) C- (1.9)
2026-10-25 C+ (2.5) C+ (2.5) D (1.3) F (0.3) C+ (2.6) D+ (1.8)
2026-10-18 C+ (2.5) C+ (2.5) D (1.3) F (0.3) C+ (2.6) D+ (1.8)
Page 1 of 3